骨转移癌的放射性核素治疗

目的:探讨核素内照射控制骨转移癌引起骨痛的作用。方法:骨转移癌患者117例,均经病理证实为恶性肿瘤,其中前列腺癌55例、肺癌39例、乳腺癌8例、结肠癌8例、胃癌2例、鼻咽癌2例、宫颈癌1例、肾癌1例、淋巴瘤1例。显像示有一处以上骨转移灶。静脉注射89Sr,剂量为4 mCi/人。结果:疼痛缓解的总有效率为71.8%(84/117),其中显效率和部分有效率分别为31.6%(37/117)、40.2%(47/117),无效率为28.2%(10/35)。来源于前列腺癌和乳腺癌的骨转移癌疼痛控制有效率达79.4%(50/63)。98例复查骨显像的患者,81例骨转移灶代谢减低、缩小或消失,占82.7%;16例原有病灶部分消失、缩小,放射性摄取减低,但有新病灶出现,占16.3%;1例较治疗前加重,占1.0%。结论:在确诊骨转移癌的病人中掌握好核素内照射治疗适应证,并与其他疗法配合可获得良好的疗效。     

SPECT结合SPECT/CT骨显像对乳腺癌骨转移的诊断价值

目的探讨SPECT结合SPECT/CT骨显像对乳腺癌骨转移的诊断价值。方法对259例患者进行SPECT及SPECT/CT骨显像,并对骨显像确诊骨转移的61例乳腺癌患者进行统计分析。结果 1)行SPECT/CT骨显像的259例乳腺癌患者中61例出现骨转移,骨转移率为23.55%,单发骨转移率27.87%,多发骨转移率72.13%。其中有10例因确诊时即发现骨转移而未行手术治疗,占16.39%;2)行手术治疗的51例乳腺癌患者分别于术后第1年至第33年不同时间行骨显像复查,术后第1年、第2年、第3年、第4年、第5年及5年以上骨转移数占受检者总数的比率分别为1.54%(4/259)、2.70%(7/259)、2.32%(6/259)、3.47%(9/259)、2.32%(6/259)及7.34%(19/259),术后2~5年骨转移占转移总数的54.90%(28/51),是骨转移高峰期;3)61例骨转移患者共发现转移灶660处,平均每例10.82处。其中胸部骨发生骨转移的病灶数最多,为244处,占36.97%;其次为脊柱骨34.85%,骨盆骨15.30%,颅骨8.18%,四肢骨4.70%,而以肋骨(29.24%)和胸椎(17.88%)最易受累;4)伴骨痛者32例,占52.46%,无骨痛者29例,占47.54%;5)SPECT结合SPECT/CT骨显像诊断溶骨性转移30例,占49.18%,成骨性转移19例,占31.15%,混合性转移12例,占19.67%。结论SPECT结合SPECT/CT骨显像对乳腺癌骨转移的诊断具有重要的临床价值。     

18F-FDG符合线路显像与99Tcm-MDP骨显像在肺癌骨转移瘤中的比较研究

目的探讨双探头带符合线路18F-脱氧葡萄糖(FDG)显像和99Tcm-亚甲基二磷酸盐(MDP)骨显像对肺癌骨转移瘤的诊断价值。资料与方法38例经病理证实的肺癌患者于2周内分别行18F-FDG符合显像和99Tcm-MDP骨显像。比较两种显像方式对两侧肩关节、脊柱、肋骨和骨盆骨转移灶检出的敏感性、特异性及准确性。最终骨转移瘤诊断标准由手术病理、CT/MR检查或临床随访半年以上范围扩大证实。结果根据骨转移的最终标准,38例患者共158处骨转移病灶,18F-FDG检出119个,99Tcm-MDP骨显像检出142个。18F-FDG与99Tcm-MDP骨显像探测骨转移的敏感性、特异性及准确性分别为65.8%、84.2%、72.7%,78.5%、81.1%、79.4%。99Tcm-MDP骨显像对骨转移灶的诊断敏感性高于18F-FDG,差异有统计学意义(χ2=6.30,P<0.05),但特异性和准确性差异均无统计学意义(χ2=0.33、3.14,P>0.05)。结论 99Tcm-MDP骨显像检测肺癌骨转移灶具有较高的敏感性,18F-FDG符合线路显像对诊断骨转移灶有一定帮助,两者联合可以提高肺癌骨转移的诊断。     

胸部X线"三阻征"与早期中央型肺癌

目的探讨胸部X线呈现"三阻征"与中央型肺癌发病的关系。方法对326例胸部X线呈现"三阻征"的肺癌高危者用螺旋CT、纤维支气管内窥镜以及痰细胞、活体和手术切除等进行中央型肺癌筛查。结果确诊为中央型肺癌者32例,患病率为9.8%;其中阻塞性肺炎21例(占12.5%),阻塞性肺气肿7例(占8.4%),阻塞性肺不张4例(占5.3%);病理类型为鳞癌16例(占50.0%),小细胞癌9例(占28.1%),腺癌4例(占12.5%),其他3例(占9.4%),首发或主要症状为胸痛者12例(占37.5%),咳嗽10例(占31.3%),咳痰5例(占15.6%),发热3例(占9.4%),血丝痰2例(占6.2%)。结论胸部X线呈现"三阻征"与中央型肺癌的发病有关,重视筛查可提高肺癌的早期检出率。     

放射性核素骨显像在前列腺癌骨转移中的研究价值

目的:探讨放射性核素骨显像与血清前列腺特异性抗原(PSA)联合检测在前列腺癌骨转移诊断中的临床意义。方法:对130例前列腺癌患者的PSA检测结果及SPECT骨显像进行回顾性分析。结果:130例前列腺癌患者,骨显像诊断骨转移86例,阳性率为66.2%。在86例骨转移的患者中,发生脊椎转移77例,占77.9%,骨盆转移65例,占75.6%,肋骨转移42例,占48.8%,肩胛骨转移11例,占12.8%,胸骨转移7例,占8.1%,颅骨转移6例,占7%。脊椎和骨盆是前列腺癌骨转移主要涉及的部位。骨显像阳性组和骨显像阴性组PSA均值差异有显著性(P<0.01),PSA<20μg/L的前列腺癌患者发生骨转移的可能性小,PSA≥20μg/L的患者发生骨转移的可能性大。结论:PSA≥20μg/L的前列腺患者应行放射性核素骨显像检查。放射性核素全身骨显像与血清PSA浓度联合检测对于前列腺癌骨转移的临床诊断具有重要的指导意义。     

国产 89SrCl2治疗肿瘤骨转移灶所致骨痛临床多中心研究

目的　验证上海科兴药业公司提供的89SrCl2 注射液治疗转移性骨肿瘤所致骨痛的疗效。方法　试验采用随机、双盲、阳性药物 (英国Amersham公司生产的Metastron)对照 ,5个中心参加验证。对 90例原发病灶诊断明确的恶性肿瘤骨转移患者进行骨痛镇痛治疗 ,其中资料完整的Ⅰ组(验证组 ) 5 9例 ,Ⅱ组 (对照组 ) 2 9例 ,余 2例患者剔除。Ⅰ组中男 30例 ,女 2 9例 ,年龄 2 5～ 80 (5 9 95±13 80 )岁 ;原发性恶性肿瘤肺癌 2 1例 ,乳腺癌 2 4例 ,前列腺癌 12例 ,胃癌、肝癌各 1例 ;治疗前骨痛评分为 6～ 12 (7 5 9± 1 5 9)。Ⅱ组中男 11例 ,女 18例 ,年龄 35～ 91(5 8 93± 14 6 0 )岁 ;原发性恶性肿瘤肺癌 10例 ,乳腺癌 12例 ,前列腺癌 6例 ,胃癌 1例 ;治疗前骨痛评分为 6～ 9(7 14± 1 4 6 )。入选患者均以 14 8MBq静脉注射给药 ,疼痛得分大于 6 ,体力状况评分平均≤ 70分 ,患者预期生存期至少大于3个月。全身99Tcm 亚甲基二膦酸盐 (MDP)骨显像示多发骨骼放射性浓聚灶 ,并经实验室及其他影像学检查证实。治疗后观察 3个月。结果　Ⅰ组镇痛有效率为 6 2 71% (37 5 9例 ) ;其中无效占 15 2 4 %(9 5 9例 ) ,好转占 2 2 0 3% (13 5 9例 ) ,显效占 5 5 93% (33 5 9例 ) ,完全缓解占 6 78% (4 5 9例 )。Ⅱ组镇     

SPECT/CT超级骨显像影像学特征、临床表现、年龄及实验室检查指标的分析

目的 探讨99Tcm-亚甲基二膦酸盐（MDP） SPECT/CT超级骨显像患者的影像学特征、临床表现、年龄及实验室检查结果的差异。 方法 收集2012年6月至2021年7月于宁夏医科大学总医院行99Tcm-MDP SPECT/CT显像的47 671例患者中呈超级骨显像的97例患者,其中男性54例、女性43例,年龄25~85（62.4±14.3）岁,回顾性分析97例患者的临床表现资料、影像学资料、年龄及实验室检查资料。根据病因不同,将患者分为骨转移瘤组（71例）与代谢性骨病组（26例,包括甲状旁腺瘤9例、肾性骨病6例、骨质疏松症11例）。根据原发肿瘤不同,将71例骨转移瘤组患者分为4个亚组[前列腺癌组（40例）、乳腺癌组（15例）、肺癌组（8例）、消化系统恶性肿瘤组（8例,包括胃癌4例、直肠癌2例、食管癌1例、原发性肝癌1例）]。统计分析骨转移瘤组与代谢性骨病组以及骨转移瘤组4个亚组之间99Tcm-MDP SPECT全身骨显像的特征、SPECT/CT融合显像的特征、临床表现、年龄和实验室检查[血钙、血磷、碱性磷酸酶（ALP）、乳酸脱氢酶（LDH）]结果的差异。计量资料的组间比较采用独立样本t检验、单因素方差分析、Wilcoxon秩和检验及Kruskal-Wallis H检验;分类变量资料的组间比较采用χ2检验。 结果 骨转移瘤（73.2%,71/97）是导致超级骨显像的最常见病因[在其原发肿瘤中,前列腺癌较常见（56.3%,40/71）],其次为代谢性骨病（26.8%,26/97）。骨转移瘤组以灶性散在分布型（Ⅱ型）为主（85.9%,61/71）,代谢性骨病组主要呈均匀对称型（ Ⅰ型）（61.5%,16/26）,2组比较差异有统计学意义（χ2=21.84,P<0.001）。骨转移瘤组以成骨型（74.6%,53/71）和混合型（19.7%、14/71）骨质破坏为主,而代谢性骨病组以溶骨型（73.1%,19/26）骨质破坏为主,差异均有统计学意义（χ2=39.76、15.95,均P<0.001）。所有患者均以骨痛为初发症状,局部骨痛为主要临床表现（56.7%,55/97）。骨转移瘤组以腰痛最常见（60.0%,24/40）,代谢性骨病组多为肋骨痛（40.0%,6/15）,2组比较差异有统计学意义（χ2=11.11,P<0.05）。骨转移瘤组患者的年龄和ALP、LDH水平均高于代谢性骨病组,而血钙水平则低于代谢性骨病组,差异均有统计学意义（t=4.89,Z=?2.28、?3.65,t=?5.96,均P<0.05）;而2组患者在血磷水平上的差异无统计学意义（t=0.01,P>0.05）。骨转移瘤组4个亚组在SPECT全身骨显像的显像模式、SPECT/CT融合显像中的骨质破坏类型、临床表现、局部骨痛部位间的差异均无统计学意义（χ2=2.71~13.07,均P>0.05） 。骨转移瘤组4个亚组间进行比较,乳腺癌组患者年龄最小、前列腺癌组患者年龄最大,乳腺癌组患者血钙水平最高,肺癌组患者LDH水平最高,且差异均有统计学意义（F=14.43、5.13,H=13.47,均P<0.05）;血磷和ALP水平的差异均无统计学意义（F=2.41,H=6.28,均 P>0.05）。 结论 超级骨显像病因中以骨转移瘤最常见,其次为代谢性骨病。2种病因超级骨显像患者在99Tcm-MDP SPECT全身骨显像、病灶处99Tcm-MDP SPECT/CT融合显像、临床表现、年龄及实验室检查结果方面均有差异,99Tcm-MDP SPECT/CT在2种病因超级骨显像的鉴别中有一定价值。     

乳腺癌患者骨病灶SPECT/CT融合显像的临床价值

目的 探讨SPECT/CT融合显像诊断与鉴别乳腺癌患者全身骨显像放射性异常浓聚灶的临床价值。 方法 对25例乳腺癌患者的99Tcm-MDP全身骨显像显示的骨异常放射性浓聚灶行SPECT/CT融合显像。4~8个月后再次行全身骨显像及SPECT/CT融合显像复查。图像由两名有经验的核医学科医师独立分析, 部分CT图像由有经验的放射科医师分析指导。 结果 在25例乳腺癌患者的37个异常放射性浓聚灶中, 确定29(29/37, 78. 38%)个病灶为骨转移灶, 其中有2个椎体病灶在初次检查中判读为良性病灶; 8(8/37, 21. 62%)个病灶为良性病灶, 其中1个肋骨病灶在初次检查中判读为骨转移灶, 比较全身骨显像和SPECT/CT融合显像, 二者之间差异有统计学意义(χ2=6.975, P < 0.05)。骨转移灶主要分布于椎骨及肋骨。全身骨显像和SPECT/CT融合显像的诊断灵敏度、特异度、阳性预测值、阴性预测值和准确率分别为82.76%、75.00%、92.31%、54.55%、81.08%和93.10%、87.50%、96.43%、77.78%、91.89%。采用受试者操作特性曲线(ROC)进行分析, 结果:全身骨显像曲线下面积为0. 860±0. 056, SPECT/CT融合显像曲线下面积为0. 974±0. 020。SPECT/CT融合显像曲线下面积大于全身骨显像曲线下面积, 两者之间差异具有统计学意义(χ2=9. 924, P < 0.001)。 结论 SPECT/CT融合显像较全身骨显像能更好地鉴别出乳腺癌骨病灶的性质, 能够提高诊断准确率, 具有重要的临床价值; 必要时应在4~8个月后复查SPECT/CT。     

肺癌、乳腺癌、食道癌远端骨转移特点的对比研究

目的 对比研究肺癌、乳腺癌、食道癌患者骨转移灶分布特点.方法　对肺癌、乳腺癌、食道癌患者454例进行 99Tcm-亚甲基二膦酸盐(99Tcm-MDP)SPECT全身骨显像,以上肢中远端和(或)骨盆、下肢部位发生骨转移为纳入条件,分析骨转移灶的分布特点及其在病种间的区别.结果 454例肿瘤患者中,上肢中远端和(或)骨盆、...     

~(18)F-NaF PET/CT与~(99m)Tc-MDP骨显像诊断乳腺癌骨转移瘤的对比研究

目的对比分析~(18)F标记的氟化钠(~(18)F-Fluoride,~(18)F-NaF) PET/CT骨显像与~(99m)Tc标记的亚甲基二膦酸盐(~(99m)Tc-MDP)骨显像(bone scintigraphy, BS)对诊断乳腺癌骨转移的临床价值。方法回顾性分析经病理证实为乳腺癌且临床怀疑骨转移的48例女性患者,在1周内分别行~(18)F-NaF PET/CT骨显像与BS检查,以病理学或临床随访结果为诊断依据,分别在病例和病灶水平上比较两种检查方法的诊断效能。结果 48例乳腺癌患者经证实38例、147个病灶为骨转移瘤。在病例水平上,~(18)F-NaF PET/CT与BS显示骨转移瘤的检出率及特异度间的差异无统计学意义(P=0.210,P=0.582),~(18)F-NaF PET/CT显示骨转移瘤的灵敏度高于BS(P0.01),~(18)F-NaF PET/CT发现乳腺癌骨转移瘤的效能与标准组高度一致(Kappa=0.934,μ=14.369,P0.01),而BS发现乳腺癌骨转移瘤的效能与标准组中等一致(Kappa=0.413,μ=2.888,P0.05)。在病灶水平上,~(18)F-NaF PET/CT发现骨转移灶的检出率、灵敏度、特异度和符合率均高于BS(χ~2=9.892,χ~2=23.263,χ~2=9.028,χ~2=30.897,P0.01),~(18)F-NaF PET/CT发现乳腺癌骨转移灶的效能与标准组高度一致(Kappa=0.881,μ=16.942,P0.01),而BS发现乳腺癌骨转移灶的效能与标准组一致性差(Kappa=0.238,μ=2.674,P0.05)。结论 ~(18)F-NaF PET/CT骨显像对乳腺癌骨转移的诊断效能总体优于BS,具有一定的临床指导意义和应用价值。     

Use of Gamma Correction Pinhole Bone Scans in Trauma

^99mTc-hydroxydiphosphonate (HDP) bone scanning is a classic metabolic nuclear imaging method and the most frequently performed examination. Clinically, it has long been cherished as an indispensable diagnostic screening tool and for monitoring of patients with bone, joint, and soft tissue diseases. The HDP bone scan, the pinhole scan in particular, is known for its ability to detect increased, decreased, or defective tracer uptake along with magnified anatomy. Unfortunately, however, the findings of such uptake changes are not specific in many traumatic bone disorders, especially when lesions are minute and complex. This study discusses the recently introduced gamma correction pinhole bone scan (GCPBS), emphasizing its usefulness in the diagnosis of traumatic bone diseases including occult fractures; cervical sprains; whiplash injury; bone marrow edema; trabecular microfractures; evident, gaping, and stress fractures; and fish vertebra. Indeed, GCPBS can remarkably enhance the diagnostic feasibility of HDP pinhole bone scans by refining the topography, pathologic anatomy, and altered chemical profile of the traumatic diseases in question. The fine and precise depiction of anatomic and metabolic changes in these diseases has been shown to be unique to GCPBS, and they are not appreciated on conventional radiographs, multiple detector CT, or ultrasonographs. It is true that MR imaging can portray proton change, but understandably, it is a manifestation that is common to any bone disease.     

螺旋CT扫描三维重建在颌骨病变的应用

本组收集了２２例螺旋扫描的颌骨病变进行三维重建，评估其在临床中的应用价值，我们认为：使用螺旋扫描所建的三维图像主要优点是：不仅仅能清楚地显示整体的颌骨病变及其周围的关系，且扫描速度快，薄层重建等。其主要缺点为降低了密度分辨率，对软组织显示差，三维ＣＴ对颌骨组织疾病的诊断和治疗均有积极的指导意义。     

脊柱转移瘤MR扫描与核素骨显像的对比研究

目的探讨脊柱骨转移瘤MR扫描阳性、核素骨显像阴性的不同原因。方法回顾经临床确诊的68例脊柱骨转移瘤病人的MRI与核素骨显像检查,分析MR影像表现,包括病灶的大小、位置及其与骨皮质关系和核素骨显像结果之间的相互联系。结果在MRI图像显示561个病灶中,核素骨显像病灶检出率35.47%(199/561)。位于骨髓内没有骨皮质侵犯的133个病灶,核素骨显像未能检出,但位于骨皮质下、经骨皮质层病灶其检出率分别为25.58%(55/215)、67.61%(144/213);小病灶组(<15mm)、大病灶组(≥15mm)病灶检出率分别为10.12%(25/247)和55.4%(174/314);相同扫描野阳性病例检出率MRI(64/68=94.12%)优于核素骨显像(49/68=72.06%),有显著差异(P<0.05)。结论脊柱转移瘤的大小、位置及骨皮质受累与否影响核素骨显像的检出率,位于骨髓内没有骨皮质侵犯的早期病灶是MR扫描阳性核素骨显像阴性的重要原因。     

Whole-Body Bone Scan Findings after High-Intensity Focused Ultrasound (HIFU) Treatment

Purpose

This study aims to examine the findings of ^99mTc-diphosphonate bone scans in cancer patients with a history of HIFU treatment.

Methods

Bone scan images of patients with a history of HIFU treatment for primary or metastatic cancer from January 2006 to July 2010 were retrospectively reviewed. Cases of primary bone tumor or HIFU treatment reaching only the superficial soft tissue layer were excluded.

Results

Bone scan images of 62 patients (26 female, 36 male; mean age 57 ± 9 years) were studied. HIFU treatment was performed in the liver (n = 40), pancreas (n = 16), and breast (n = 6). Mean interval time between HIFU treatment and bone scan was 106 ± 105 days (range: 1–572 days). Of 62 scans, 43 showed diffusely decreased uptake of bone within the path of HIFU treatment: antero-axillary and/or posterior arcs of right 5th to 11th ribs in 34 cases after treatment of hepatic lesions; anterior arcs of 2nd to 5th ribs in 5 cases after treatment for breast tumors; and posterior arcs of left 9th to 11th ribs or thoraco-lumbar vertebrae in 4 cases after treatment for pancreas tumor. Of 20 patients who had bone scans more than twice, five showed recovered uptake of the radiotracer in the involved ribs in the follow-up bone scan.

Conclusion

Of 62 bone scans in patients with a history of HIFU treatment for primary or metastatic cancer, 69% presented diffusely decreased uptake in the bone in the path of HIFU treatment.     

Depiction of Nidi and Fibrovascular Zones of Osteoid Osteomas Using Gamma-Correction Tc-99m HDP Pinhole Bone Scan and Conventional Radiograph,and Correlation with CT,MRI, and PVC Phantom Imaging

Purpose

For the precise imaging diagnosis of osteoid osteoma (OO), the identification of the nidus and fibrovascular zone (FVZ) is essential. However, the latter sign has received little attention because it is difficult to demonstrate. We applied the recently introduced gamma correction (GC) to depict the FVZ on pinhole bone scan (PBS), conventional radiography (CR), and computed tomography (CT). Non-gamma correction MRI was also analyzed for reference.

Methods

Ten patients with histologically proven diagnoses of OO were enrolled in this retrospective study. PBS, CR, and CT were processed by GC to demonstrate the nidi and FVZ as distinct yet integrating components of OO. PBS was performed using a 4-mm pinhole collimator 3 h after iv injection of 925 to 1,110 MBq (25 to 30 mCi) of Tc-99m HDP, and anteroposterior and mediolateral CR and transverse CT were taken according to the standard technique. MRI sequences included T1- and T2-weighted images. For gamma correction, we utilized the Photo Correction Wizard program of ACD Photo Editor v3.1. A team of three qualified nuclear physician-radiologists, two nuclear physicians, and one MRI specialist read bone scans, radiographs, and MRIs of OO according to each specialty, and orthopaedic aspects and histology were reviewed by one qualified orthopedic surgeon and two qualified pathologists, respectively. Each observer first read the images separately with basic information about the aim of the study given and then in concert. Interpretive disagreement was settled by discussion and consensus.

Results

On pinhole scan, nidi were presented as areas of intense tracer uptake in all cases, and, importantly after GC, a thin ring-like zone with lower tracer uptake became visible in seven out of ten cases. GCCR also revealed a thin lucent zone that circumscribed the nidi in six out of ten cases and GCCT in two of four cases. MRI, without GC, presented nidi with high signal in the center and a thin ring-like zone with low signal in the periphery in five out of six cases. Ring-like zones were 1–2 mm in thickness and circumscribed the nidus as an integrated part and, hence, were morphologically interpreted as FVZ. Histologically, the presence of a variously mineralized FVZ was confirmed in four cases, but individual locus-by-locus image-histology correlation could not be accompolished because specimens were fragmentary. In the FVZ, tracer uptake was lower than in nidi, presumably reflecting that bone metabolism in the two parts differs as in their histology. Statistically, no significant correlation existed between the duration of symptoms and imaging demonstrability of the FVZ (Spearman’s test r = −0.057, p = 0.877), but parallelism existed in the demonstrability of the FVZ among GC PBS, CR, and CT, and non-correction MRI.

Conclusions

GC was useful to enhance the resolution of PBS, CR, and CT in OO so that both the nidi and FVZ were separately imaged. The use of CG PBS and CR in combination is recommended for the specific diagnosis of OO with information about bone metabolism and anatomical characteristics. PBS and CR are economical and widely available.     

Bone and skeletal muscle metastases from gastric adenocarcinoma: unusual radiographic, CT and scintigraphic features

Skeletal metastatic lesions arising from gastric cancer are uncommon and usually of the osteolytic type. In order to gain a better understanding of its radiological spectrum, we report two atypical cases of skeletal metastases from gastric adenocarcinoma presenting with unusual radiographic, CT and scintigraphic features. In one patient multiple ossifying skeletal muscle metastases and bone metastases with spiculated periosteal reaction occurred as a presenting manifestation of the malignant disease. The other patient developed widespread osteosclerotic metastases with a superscan pattern on bone scintigraphy. Received 18 July 1997; Revision received 14 November 1997; Accepted 9 December 1997     

Diagnostic Performance of Three-Phase Bone Scan for Complex Regional Pain Syndrome Type 1 with Optimally Modified Image Criteria

Purpose

Although the three-phase bone scan (TBPS) is one of the widely used imaging studies for diagnosing complex regional pain syndrome type I (CRPS-1), there is some controversy regarding the TPBS image criteria for CRPS-1. In this study, we modified the image criteria using image pattern and quantitative analysis in the patients diagnosed using the most recent consensus clinical diagnostic criteria.

Materials and Methods

The study included 140 patients with suspected CRPS-1 (CRPS-1, n = 79; non-CRPS, n = 61; mean age 39 ± 15 years) who underwent TPBS. The clinical diagnostic criteria for CRPS-1 revised by the Budapest consensus group were used for confirmative diagnosis. Patients were classified according to flow/pool and delayed uptake (DU) image patterns, and the time interval between the initiating event and TPBS (TI_event-scan). Quantitative analysis for lesion-to-contralateral ratio (LCR) was performed. Modified TPBS image criteria were created and evaluated for optimal diagnostic performance.

Results

Both increased and decreased periarticular DU were significant image findings for CRPS-1 (CRPS-1 positive-rate = 73% in the increased DU group, 75% in the decreased DU group). The TI_event-scan did not differ significantly between the different image pattern groups. Quantitative analysis revealed an LCR of 1.43 was the optimal cutoff value for CRPS-1 and diagnostic performance was significantly improved in the increased DU group (area under the curve = 0.732). Given the modified image criteria, the sensitivity and specificity of TPBS for diagnosing CRPS-1 were 80% and 72%, respectively.

Conclusions

Optimally modified TPBS image criteria for CRPS-1 were suggested using image pattern and quantitative analysis. With the criteria, TPBS is an effective imaging study for CRPS-1 even with the most recent consensus clinical diagnostic criteria.     

脱钙骨/聚乳酸重组人工骨的制备及性能测试

目的研制性能优良的人工骨材料并测试其相关性能。方法将脱钙骨、聚乳酸、氯化钠按比例复合,利用模压增强法制备重组人工骨(BPCB)材料,检测其孔隙率、孔径、生物力学强度等性能参数,并与有机溶剂注模颗粒沥滤法制备的材料进行比较。结果研制的BPCB材料孔隙率为55.20%、孔径为227.33μm、压缩强度为5.52MPa、弯曲强度为19.61MPa。与有机溶剂注模颗粒沥滤法相比,模压增强法制备的材料强度更高。结论BPCB材料的孔隙率、孔径、生物力学强度等性能均符合骨替代材料的要求。     

血清骨钙素在高转运型骨病诊断中的意义

目的探讨血透病人血清骨钙素水平在高转运型骨病诊断中的意义。方法收集62例(平均年龄55.42±14.67岁)维持性血透病人一般临床资料、测定血清钙(Ca)、磷(P)、钙磷乘积(Ca×P)、碱性磷酸酶(ALP)、全段甲状旁腺素(iPTH)及骨钙素(BGP)。以iPTH>450 ng/L为标准一(A组)及iPTH>450 ng/L、BGP>8μg/L为标准二(B组)分别预测高转运型骨病。结果两组病人血清Ca、P、Ca×P及ALP无明显差异。标准一预测高转运型骨病病人占纳入病例的50.7%,其中BGP<1.5μg/L占33%。标准二预测高转运型骨病占纳入病例的38.5%。结论血透病人血清BGP及iPTH水平明显升高(P>0.01,P>0.01),血清BGP与iPTH同时用以预测高转运型骨病具有十分重要的临床意义。     

月经初潮早晚对女大学生骨骼生长发育与骨量的影响

目的：探讨月经初潮早晚对女大学生骨骼生长发育与骨量的影响。方法：以５５名女大学生为研究对象，测量身高、骨密度（ＢＭＤ）、骨宽等指标。结果：月经初潮早晚对身高、尺骨宽、桡骨宽影响较小，而尺骨ＢＭＤ、桡骨ＢＭＤ随着月经初潮年龄的逐渐增长大致呈依次递减的规律，并且组间比较呈显著性差异（Ｐ＜０．０５或Ｐ＜０．０１）。结论：月经初潮早晚对女大学生骨骼发育与骨量有一定的影响，表现为月经初潮早的学生比月经初潮晚的学生骨形成活动更活跃，积累了更多的骨矿物质，这主要是由于月经初潮早晚对女性体内性激素水平有影响，而性激素水平又直接影响骨代谢活动。